Indications -- cardiovascular Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- cardiovascular

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	8/20/2002 10:44:29 AM
From: scaram(o)uche	of 214

Researchers demonstrated that the selective loss of macrophage LXR activity significantly increased atherosclerotic lesion development. "This demonstrates that the LXRs are protective or anti-atherogenic and thereby represent a novel molecular target for the treatment of cardiovascular disease," stated Dr. Richard Heyman, Chief Scientific Officer at X-Ceptor Therapeutics. These studies were performed by replacing normal macrophages with LXR-deficient macrophages in mice using bone marrow transplantation. The results demonstrate that these receptors function as endogenous inhibitors of atherosclerosis. Although previous studies have shown that LXRs are important regulators of cholesterol levels in the body, this study is the first to show a direct link between macrophage LXR activity and its role in the inhibition of atherosclerosis. Message 17897743

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next